Patents Issued in August 14, 2018
  • Patent number: 10045993
    Abstract: The present invention relates to a pharmaceutical preparation comprising entecavir as an active ingredient, wherein an antioxidizing agent is added to enhance stability of entecavir, and a method for preparing the same. According to the present invention, the invention has an effect that entecavir can be stably maintained in a pharmaceutical preparation containing a certain amount or more of moisture by adding the antioxidizing agent, thereby a pharmaceutical preparation can be provided as a formulation containing a certain amount or more of moisture, for example, an orally disintegrating film formulation.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: August 14, 2018
    Assignee: CTC BIO, INC.
    Inventors: Hong Ryeol Jeon, Do-Woo Kwon, Bong-Sang Lee, Su-Jun Park, Jiyeong Han, Myeongcheol Kil, Min Seop Kim
  • Patent number: 10045994
    Abstract: The present invention relates to the use of compounds of a cannabinoid nature for inhibiting viability with increasing doses of myeloma cell lines. Furthermore, said compounds have been shown not to affect CD34+ cells (normal hematopoietic progenitors) in terms of viability and proliferation. For this reason, the invention paves the way for the use of compounds of a cannabinoid nature as a promising therapy against multiple myeloma and related diseases.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: August 14, 2018
    Assignee: SERVICIO ANDALUZ DE SALUD
    Inventors: José Antonio Pérez Simón, María Victoria Barbado González
  • Patent number: 10045995
    Abstract: The present invention relates to an epidithiodioxopiperazine derivative represented by the following Chemical Formula 1 or its reduced derivative; a method for preparing a compound represented by Chemical Formula 1 having improved intracellular permeability and mimicking the activity of 2-Cys-Prx in its reduced form in the cells; a pharmaceutical composition for preventing or treating vascular diseases comprising an epidithiodioxopiperazine compound or its derivatives or pharmaceutically acceptable salts thereof as an active ingredient; a drug delivery device for local administration including the pharmaceutical composition; and a pharmaceutical composition for inhibiting melanoma metastasis comprising the epidithiodioxopiperazine compound or its derivatives or pharmaceutically acceptable salts thereof as an active ingredient.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: August 14, 2018
    Assignee: EWHA University Industry-Collaboration Foundation
    Inventors: Sang Won Kang, Dong Hoon Kang, Doo Jae Lee
  • Patent number: 10045996
    Abstract: The invention provides novel pharmaceutical compositions for the treatment of increased intraocular pressure based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble prostaglandin analogues. The compositions can be administered topically into the eye. The invention further provides kits comprising such compositions.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: August 14, 2018
    Assignee: NOVALIQ GMBH
    Inventors: Bastian Theisinger, Sonja Theisinger, Bernhard Günther
  • Patent number: 10045997
    Abstract: New compositions for and methods of treating ocular hypertension provide for effective treatment of ocular hypertension often using reduced concentrations of active components. Such compositions include a timolol component and a hypotensive lipid component. The present compositions and methods are relatively straightforward, can be easily produced, for example, using conventional manufacturing techniques, and can be easily and conveniently practiced, for example, using application or administration techniques or methodologies which are substantially similar to those employed with prior compositions used to treat ocular hypertension.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: August 14, 2018
    Assignee: ALLERGAN, INC.
    Inventors: June Chen, David F. Woodward, Alexander B. Kharlamb
  • Patent number: 10045998
    Abstract: Combinations of (3?)-17-(pyridin-3-yl)androsta-5,16-dien-3-yl acetate (Abiraterone acetate) with acidic substances such as citric acid, ascorbic acid, methyl-4-hydroxy benzoate, saccharin, vanillic acid, adipic acid, maleic acid, malic acid, tartaric acid are useful as pharmaceutical preparations and show improved properties such as aqueous solubility and dissolution kinetics, especially in the form of cocrystals or their combination with a suitable acid.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: August 14, 2018
    Assignee: BASF SE
    Inventors: Tiziana Chiodo, Beate Salvador, Marcus Vossen, Andreas Hafner, Tobias Hintermann, Martin Szelagiewicz, Fritz Blatter, Martin Viertelhaus, Walter Weishaar
  • Patent number: 10045999
    Abstract: The invention relates to the use of an anabolic amino acid derivative stimulus acting in combination with vitamin D for the manufacture of a medicament or nutritional composition for the prevention and/or treatment of a loss of any one of muscle mass, muscle strength, muscle function, and physical function, or any combination thereof, in a mammal.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: August 14, 2018
    Assignee: N. V. Nutricia
    Inventors: Marion-Eve Adeline Jourdan, Yvette Charlotte Luiking, George Verlaan, Sovianne Ter Borg
  • Patent number: 10046000
    Abstract: Disclosed are methods of administering 2-methylene-19-nor-(20S)-1?,25-dihydroxyvitamin D3 to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: August 14, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Lori A. Plum, Julia B. Zella, Margaret Clagett-Dame
  • Patent number: 10046001
    Abstract: Compositions, kits, and methods for reducing intraocular pressure (IOP) in a subject (e.g., human) include at least one naturally occurring or synthesized version or analog thereof of a lipid (e.g., a phosphoserine, a phosphocholine, a psychosine or other glycolipid) that is endogenous to non-glaucomatous aqueous humor in a subject and that lowers IOP in the subject, in a therapeutically effective amount for promoting aqueous outflow through TM in at least one eye of the subject and reducing IOP in the subject. The compositions can be used for, e.g., treating glaucomas, including, for example, primary open angle glaucoma (POAG) and normal tension glaucoma (NTG).
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: August 14, 2018
    Assignee: UNIVERSITY OF MIAMI
    Inventors: Richard K. Lee, Sanjoy K. Bhattacharya
  • Patent number: 10046002
    Abstract: What is described is a method for treating cancer in a patient in need of such treatment through the use of an antagonist to CXCR1 and/or CXCR2 receptors by administering a therapeutically effective amount of an antagonist of CXCR1 and/or CXCR2, or pharmaceutical compositions thereof, either alone as monotherapy, or in combination with at least one other anticancer therapy.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: August 14, 2018
    Assignee: SYNTRIX BIOSYSTEMS INC.
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • Patent number: 10046003
    Abstract: The present disclosure relates to a composition comprising eleutheroside-C, pinitol and sugars optionally along with pharmaceutically acceptable excipient or a combination thereof; a process of obtaining said composition from fenugreek seeds, a method of treating neuropathic pain or managing neuropathy, and the use of the said composition in treating neuropathic pain or managing neuropathy.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: August 14, 2018
    Assignee: INDUS BIOTECH PRIVATE LIMITED
    Inventors: Sunil Bhaskaran, Mohan Vishwaraman
  • Patent number: 10046004
    Abstract: The present disclosure relates to treatment of a pulmonary disease. The methods and kits provided herein facilitate relieving the symptoms resulting from the pulmonary disease (e.g., asthma, chronic obstructive pulmonary disease (COPD), etc.).
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: August 14, 2018
    Assignee: Shanghai KE Pharmaceutical Co., LTD
    Inventors: Minsheng Zhu, Jie Sun, Yang Pan
  • Patent number: 10046005
    Abstract: A composition and associated method for treating a hepatitis C virus (HCV) infection in a subject who is human being. The composition includes: an anti-viral agent and/or a protease inhibitor; a polymerase inhibitor; one or more viral entry inhibitors; and one or more anti-fibrotic agents and/or anti-hemolytic agents including one or more Polyphenols and/or one or more Thiols. The composition may also include one or more sulfated oligosaccharide or non-anticoagulant glycosaminoglycans (GAGs). The method administers, to the subject, a therapeutic dose of the composition to treat the subject for the HCV infection.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: August 14, 2018
    Inventor: Shaker A. Mousa
  • Patent number: 10046006
    Abstract: Methods for reducing recruitment, migration, or both recruitment and migration of polymorphonuclear cells to a site of inflammation in an organ of a human patient comprise administering locally to the organ or systemically to the patient in need thereof an isolated oligonucleotide selected from the group consisting of SEQ ID NO: 8 (IDX9059); SEQ ID NO: 14 (IDX9052); SEQ ID NO: 7 (IDX9054); SEQ ID NO: 6 (IDX9045); SEQ ID NO: 1 (IDX9005); SEQ ID NO: 9 (IDX9074); SEQ ID NO: 3 (IDX9022); SEQ ID NO: 2 (IDX9010); SEQ ID NO: 4 (IDX9030); and SEQ ID NO: 13 (IDX0150).
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: August 14, 2018
    Assignee: InDex Pharmaceuticals AB
    Inventors: Charlotte Admyre, Lars-Göran Axelsson, Oliver Von Stein, Arezou Zargari
  • Patent number: 10046007
    Abstract: The invention generally relates to methods of treating short telomere disorders using known compounds and pharmaceutical compositions comprising same. More specifically, the disclosed methods comprise, in one aspect, the step of administering to the subject an effective amount of at least one lithium compound or a pharmaceutically acceptable salt thereof, thereby treating the subject for the short telomere disorder. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: August 14, 2018
    Assignee: Prescient Pharma, LLC
    Inventors: Pavel Idelevich, Yanming Wang
  • Patent number: 10046008
    Abstract: The present invention relates generally to the treatment of PML by infusion of activated and expanded autologous lymphocytes.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: August 14, 2018
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, Anne Chew, Stephen J. Schuster
  • Patent number: 10046009
    Abstract: The invention relates to a pharmaceutical composition containing a PLP-dependent enzyme and optionally its cofactor, pyridoxal phosphate (PLP), and/or a phosphate or non-phosphate precursor of PLP, its use as a drug, its production method and a therapeutic treatment method related to it. The pharmaceutical composition comprises erythrocytes and a pharmaceutically acceptable vehicle, the erythrocytes encapsulating the PLP-dependent enzyme. The PLP-dependent enzyme may be methioninase, tyrosine phenol-lyase, tyrosine aminotransferase or cystathionine beta-synthase.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: August 14, 2018
    Assignee: ERYTECH PHARMA
    Inventors: Yann Godfrin, Vanessa Bourgeaux, Fabien Gay, Thomas Cortese
  • Patent number: 10046010
    Abstract: A method of generating MSCs which secrete neurotrophic factors (NTFs) comprising incubating a population of undifferentiated mesenchymal stem cells (MSCs) in a differentiating medium comprising basic fibroblast growth factor (bFGF), platelet derived growth factor (PDGF), heregulin and cAMP.
    Type: Grant
    Filed: August 4, 2013
    Date of Patent: August 14, 2018
    Assignee: BrainStorm Cell Therapeutics Ltd.
    Inventors: Yael Gothelf, Yosef Levy, Alex Burshtein
  • Patent number: 10046011
    Abstract: The present invention provides methods or kits with inflammatory cytokines to pretreat 1-ISCs to augment their immune modulatory effect, in prevention and treatment of various diseases such as multiple sclerosis, arthritis, lupus, sepsis, hepatitis, cirrhosis, Parkinson's disease, chronic infections, and GvHD. The present invention relates to novel methods for enhancing the immunosuppressive or the immune stimulatory activities of mesenchymal stem cells (JvfSCs).
    Type: Grant
    Filed: December 14, 2013
    Date of Patent: August 14, 2018
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Yufang Shi, Guangwen Ren, Liying Zhang
  • Patent number: 10046012
    Abstract: The invention generally relates to postnatal periodontal ligament stem cells and methods for their use. More specifically, the invention relates in one aspect to postnatal periodontal ligament multipotent stem cells, use of the cells to generate periodontium, differentiation of the cells and methods of tissue cryopreservation.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: August 14, 2018
    Assignee: The United States of America as represented by the Secretary, Department of Health and Human Services
    Inventors: Songtao Shi, Byoung-Moo Seo, Masako Miura
  • Patent number: 10046013
    Abstract: Disclosed is an oral delivery system that overcomes major barriers encountered in the gastrointestinal tract, particularly rapid proteolytic degradation and low intestinal permeability. Provided is a method for oral delivery of an engineered microorganism to a mammal where the microorganism produces a macromolecule having a desired bioavailability outcome.
    Type: Grant
    Filed: March 8, 2012
    Date of Patent: August 14, 2018
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Casim Ali Sarkar, Ting Wun Ng
  • Patent number: 10046014
    Abstract: The present invention relates to the cosmetic use of a lysate of a bacterium or bacteria belonging to the Vitreoscilla sp. genus (in particular the species: Vitreoscilla filiformis) in a complete fermentation medium, as an active agent for preventing and/or treating dandruff conditions of the scalp, including dandruff conditions of the scalp associated with a prevalence of pathogenic microorganisms on the scalp and/or an imbalance of the scalp ecoflora.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: August 14, 2018
    Assignee: L'OREAL
    Inventors: Pascal Hilaire, Yann Mahe, Richard Martin
  • Patent number: 10046015
    Abstract: The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: August 14, 2018
    Assignee: 4D Pharma Research Limited
    Inventors: Imke Elisabeth Mulder, Amy Beth Holt, Seanin Marie McCluskey, Grainne Clare Lennon, Suaad Ahmed
  • Patent number: 10046016
    Abstract: The present invention provides mutant adeno-associated virus (AAV) that exhibit altered capsid properties, e.g., reduced binding to neutralizing antibodies in serum and/or altered heparin binding and/or altered infectivity of particular cell types. The present invention further provides libraries of mutant AAV comprising one or more mutations in a capsid gene. The present invention further provides methods of generating the mutant AAV and mutant AAV libraries, and compositions comprising the mutant AAV. The present invention further provides recombinant AAV (rAAV) virions that comprise a mutant capsid protein. The present invention further provides nucleic acids comprising nucleotide sequences that encode mutant capsid proteins, and host cells comprising the nucleic acids. The present invention further provides methods of delivering a gene product to an individual, the methods generally involving administering an effective amount of a subject rAAV virion to an individual in need thereof.
    Type: Grant
    Filed: July 28, 2014
    Date of Patent: August 14, 2018
    Assignees: The Regents of the University of California, Integrative Gene Therapeutics
    Inventors: David V. Schaffer, Brian Kaspar, Narendra Maheshri
  • Patent number: 10046017
    Abstract: Use of a pomegranate skin extract for use in the treatment of metabolic syndrome, more particularly, fatty liver disease. More particularly, the pomegranate skin extract is used in inhibiting body weight gain in the prevention and/or the treatment of fatty liver disease in mammals.
    Type: Grant
    Filed: January 9, 2014
    Date of Patent: August 14, 2018
    Assignee: Nestec S.A.
    Inventors: Ignatius Szeto, Peifang Zhang, Weiguo Zhang, Junkuan Wang, Chieh Jason Chou
  • Patent number: 10046018
    Abstract: Methods and formulations for increasing the water solubility and/or bioavailability of a phytocannabinoid compound is disclosed herein. In one example, a water-soluble phytocannabinoid formulation can comprise a phytocannabinoid; a non-ionic surfactant; and optionally, water. The weight ratio of phytocannabinoid content to non-ionic surfactant can be from 1:10,000 to 1:5.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: August 14, 2018
    Inventor: Eric Kuhrts
  • Patent number: 10046019
    Abstract: The present invention relates to inventive novel industrialized method for preparing purified extract containing more abundant active ingredients such as catalpol derivatives from the extract of Pseudolysimachion rotundum var subintegrum than that prepared by the conventional preparation method disclosed in the prior art and the therapeutics or functional health food comprising the purified extract for treating and preventing inflammatory, allergic or asthmatic disease. The purified extract showed more potent anti-inflammatory, anti-allergy and anti-asthma activity than that prepared by the conventional preparation method disclosed in the prior art through various in vivo tests such as inhibition test on the reproduction of eosinophil, the release of immunoglobulin and inflammatory chemokines in plasma and bronchoalveolar fluid as well as the suppression of airway hyperresponsiveness and goblet cell hyperplasia in a OVA-sensitized/challenged mouse model.
    Type: Grant
    Filed: September 11, 2016
    Date of Patent: August 14, 2018
    Assignees: YUNGJIN PHARMACEUTICAL CO., LTD, KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Yongnam Lee, Ji-seok Yoo, Dae-hee Shin, Byung-hwan Ryoo, Sei-ryang Oh, Kyung-seop Ahn, Hyeongkyu Lee, Ok-kyoung Kwon, Doo-young Kim, Jung-hee Kim, Hyuk-hwan Song
  • Patent number: 10046020
    Abstract: The present invention relates to the use of compounds selected from the group consisting of Lys-(D)Pro-Thr, N-acyl Lys-(D)Pro-Thr, C-amide Lys-(D)Pro-Thr, and C-esters of Lys-(D)Pro-Thr; or a pharmaceutically acceptable salt of said compound for the treatment of inflammatory disorders. The invention also relates to the use of ?MSH for inducing tolerance.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: August 14, 2018
    Inventor: Thomas Luger
  • Patent number: 10046021
    Abstract: The present invention provides phosphorylcholine conjugates and pharmaceutical compositions comprising same for the prevention or treatment of autoimmune diseases. In particular, the conjugates of the present invention are effective in treating autoimmune diseases associated with pathological inflammation.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: August 14, 2018
    Assignee: TPCERA LTD.
    Inventors: Yehuda Shoenfeld, Miriam Blank
  • Patent number: 10046022
    Abstract: Provided are a synthetic peptide that increases the radiosensitivity of tumor cells and a pharmaceutical composition containing that synthetic peptide. The peptide provided by the present invention is a synthetic peptide having a radiosensitizing peptide sequence including the following amino acid sequence: CX2X3KX5X6X7X8C (wherein, X2 represents K or R, X3 represents S or A, X5 represents S or A, X6 represents R or G, X7 represents R or D and X8 represents S or P); or, a modified amino acid sequence in which one, two or three amino acid residues are substituted, deleted and/or added in that amino acid sequence. In addition, the pharmaceutical composition provided by the present invention is a composition used to increase the sensitivity of tumor cells to radiation in tumor radiation therapy, and contains the synthetic peptide described above.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: August 14, 2018
    Assignee: TOAGOSEI CO. LTD.
    Inventors: Nahoko Baileykobayashi, Noriko Usami, Tetsuhiko Yoshida
  • Patent number: 10046023
    Abstract: The invention provided herein includes isolated polypeptides that specifically block the interaction between neonatal Fc receptor (FcRn) and albumin. Blocking the interaction treats diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties wherein it is deemed desirable to decrease albumin levels. Accordingly, also provided are methods of using these isolated polypeptides to treat various diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties. The invention provided herein also includes isolated polypeptides capable of binding to a non-IgG and non-albumin competitive site on an FcRn alpha 3 domain. These can be useful for tracking FcRn without inhibiting IgG or albumin binding or function. Accordingly, the invention also includes methods and systems to track FcRn without inhibiting IgG or albumin binding or function.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: August 14, 2018
    Assignees: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., BIOGEN MA INC.
    Inventors: Richard S. Blumberg, Timo Rath, Kristi Baker, Adam Mezo, Zachary Taylor, Kevin McDonnell, Rosa Maria Silva Garcia Grenha
  • Patent number: 10046024
    Abstract: A composition which is reversible inhibitor of at least one neuron-specific PDZ domain comprising wherein R is a molecular transporter with or without a linker amino acid; R1 is at least about one amino acid covalently bound; and, R2 is isoleucine, leucine, alanine, phenylalanine, or valine, and methods of use.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: August 14, 2018
    Assignee: The United States of America, as represented by National Institutes of Health (NIH), U.S. Dept of Health and Human Services (DHHS), NIH Division of Extramural Inventions and Technology Resource (DEITR)
    Inventors: Mark Spaller, John Marshall, Dennis J. Goebel
  • Patent number: 10046025
    Abstract: The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a cyclic polypeptide.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: August 14, 2018
    Assignee: Aegis Therapeutics, LLC
    Inventor: Edward T. Maggio
  • Patent number: 10046026
    Abstract: This invention relates, e.g., to a virus-like particle (VLP) composition assembled from a chimeric polypeptide comprising a papilloma virus (e.g., human papillomavirus, or HPV) L1 major capsid protein, into which is inserted a surface-displayed peptide comprising a neutralizing epitope of a papillomavirus L2 protein. Vaccine compositions comprising the VLP are described, as well as methods for inducing an immune response (e.g., vaccinating) a subject against papilloma virus, using the VLP, and kits comprising the VLP, for carrying out a method of the invention.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: August 14, 2018
    Assignee: The Johns Hopkins University
    Inventors: Richard B. S. Roden, Reinhard Kirnbauer, Christina Schellenbacher
  • Patent number: 10046027
    Abstract: The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: August 14, 2018
    Assignee: PIERIS PHARMACEUTICALS GMBH
    Inventors: Kristian Jensen, Martin Huelsmeyer, Steffen Schlehuber, Andreas Hohlbaum, Arne Skerra, Eric Boudreau, Richard Jones, Ian Kimber, Rebecca Dearman
  • Patent number: 10046028
    Abstract: Disclosed herein are methods and compositions for modulating expression of a PD1 gene.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: August 14, 2018
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Philip D. Gregory, Michael C. Holmes, Matthew C. Mendel, Xiangdong Meng, David Paschon, Andreas Reik, Fyodor Urnov
  • Patent number: 10046029
    Abstract: The present invention relates to a combination of at least two different substances, one of which activates the STAT1-signalling cascade and the other of which activates the TNFR1/CD95-signalling cascade in order to induce permanent growth arrest—i.e. senescence—in pre-malignant or malignant tumors or tumor cells. This induction of permanent growth arrest does not depend on cytotoxicity and does not primarily attempt to kill tumor cells, although this may occur. The induction serves to treat and/or prevent tumors by permanent growth arrest. The combination is used for therapeutic or preventative senescence induction in tumors, in which the STAT1- and TNFR1/CD95-signalling cascade can be activated and in which p16lnk4a is present. The invention transfers tumor cells and, contrary to many other therapies, the tumor stem cells, into permanent growth arrest.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: August 14, 2018
    Inventor: Martin Roecken
  • Patent number: 10046030
    Abstract: The present invention encompasses compositions and methods useful to treat or prevent Clostridium difficile antibiotic-associated colitis through administration of IL-25 and/or downstream cytokines IL-13, IL-4, and IL-5. It is disclosed herein that IL-25 expression is decreased during antibiotic treatment and during bacterial infection and that treatment with IL-25 protein is protective during infection. It is further disclosed herein the unexpected result that IL-25 treatment protects against C. difficile-associated mortality and morbidity. The present application further describes an unexpected result regarding eosinophils and their role in combating infection and their relationship to the effectiveness of IL-25.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: August 14, 2018
    Assignee: University of Virginia Patent Foundation
    Inventors: William A. Petri, Jr., Erica Buonomo
  • Patent number: 10046031
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: August 14, 2018
    Assignee: MannKind Corporation
    Inventors: Anders Hasager Boss, Richard Petrucci, Campbell Howard, Alfred Mann
  • Patent number: 10046032
    Abstract: The present disclosure provides means and methods for promoting gastric emptying. In particular, the present disclosure provides the use of insulin or a composition comprising same for promoting gastric emptying and for treating gastric disorders, particularly disorders characterized by delayed gastric emptying. The insulin or composition comprising same are to be administered enterally.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: August 14, 2018
    Assignee: Nutrinia, LTD.
    Inventors: Tal Atarot, Michal Olshansky
  • Patent number: 10046033
    Abstract: The present application provides for compositions comprising high concentrations of acid a-glucosidase in combination with an active site-specific chaperone for the acid ?-glucosidase, and methods for treating Pompe disease in a subject in need thereof, that includes a method of administering to the subject such compositions. The present application also provides methods for increasing the in vitro and in vivo stability of an acid ?-glucosidase enzyme formulation.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: August 14, 2018
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Kenneth Valenzano, John Crowley, Richie Khanna, John Flanagan
  • Patent number: 10046034
    Abstract: The invention relates to a hemostatic composition in powder form comprising collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen, and at least one monosaccharide, and optionally, at least one compound selected from coagulation factors and glycosaminoglycans. The invention further relates to a method for preparing such composition, and to a unit comprising such composition and a spraying device.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: August 14, 2018
    Assignee: BIOM'UP
    Inventors: Christian Gagnieu, Patricia Forest, Sylvain Picot
  • Patent number: 10046035
    Abstract: This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: August 14, 2018
    Assignee: SYNTHETIC BIOLOGICS, INC.
    Inventors: Michael Kaleko, Sheila Connelly, Vincent John Wacher
  • Patent number: 10046036
    Abstract: The invention provides reagents and methods for enzyme replacement therapy using chemically modified species of human cystathionine ?-synthase (CBS) to treat homocystinuria and other related diseases and disorders.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: August 14, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Jan P Kraus, Tomas Majtan, Erez Bublil
  • Patent number: 10046037
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: August 14, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffen Walter, Harpreet Singh
  • Patent number: 10046038
    Abstract: The antigenic mass of Leptospira cultures can be significantly increased, independent from any increase in biomass, by supplementing Leptospira cultures with a specific type of fatty acid: a polyunsaturated C18 fatty acid. This provides advantages in the production Leptospira antigens. Also this enables the production of improved Leptospirosis vaccines, that are safer and more effective.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: August 14, 2018
    Assignee: Intervet Inc.
    Inventors: Christian Theodoor Gerardus Smits, Edwin Kets, Henriette Adriaanse
  • Patent number: 10046039
    Abstract: Disclosed are stable conjugate vaccine formulations for protection against Salmonella typhi, and methods of conjugation between Vi-polysaccharide of S. typhi to tetanus toxoid as the carrier protein, responsible for producing improved T-dependent immune response against Typhoid fever caused by Salmonella typhi. The methods disclosed in this invention and the resulting formulations are capable of inducing immunity against typhoid fever including in children below 2 years of age, through only a single injection to comprise a complete vaccination schedule.
    Type: Grant
    Filed: August 19, 2014
    Date of Patent: August 14, 2018
    Assignee: Bharat Biotech International Limited
    Inventors: Krishna Murthy Ella, Venkatesan Ramasamy, Mandalapu Gangadhara Naidu
  • Patent number: 10046040
    Abstract: The invention relates to a multivalent Clostridium difficile vaccine comprising a Salmonella Typhi live vector comprising the cell binding domain of TcdA toxin (CBD/A) of Clostridium difficile or an antigenic fragment thereof and the cell binding domain of TcdB toxin (CBD/B) of Clostridium difficile or an antigenic fragment thereof and optionally the cell-binding subunit component (CdtB) of binary toxin of Clostridium difficile or an antigenic fragment thereof. The invention further provides methods of inducing an immune response and methods of preventing recurrence of C. difficile infections in subjects.
    Type: Grant
    Filed: November 16, 2010
    Date of Patent: August 14, 2018
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventor: James E. Galen
  • Patent number: 10046041
    Abstract: The present invention is directed to methods of suppressing the virulence of one or more virulence antigenic factors of methicillin resistant Staphylococcus aureus (MRSA). Aspects of the invention include administering of an expression vector alone or in conjunction with a fusion protein. The expression vector has a transcription unit encoding a fusion protein composed of a virulence antigenic factor of MRSA attached through a linker to the aminoterminal end of the ecd CD40 ligand. The fusion protein is composed of a virulence antigenic factor of MRSA and CD40 ligand and has the ability to generate antibodies which prevents host cell infection by suppressing virulence functions of MRSA.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: August 14, 2018
    Assignee: MicroVAX, LLC
    Inventor: Albert B. Deisseroth
  • Patent number: 10046042
    Abstract: The present invention provides a meningococcal conjugate vaccine for groups A, C, Y and W135, which is a tetravalent conjugate vaccine comprising polysaccharide-protein conjugates obtained by respectively conjugating a capsular polysaccharide of Neisseria meningitides groups A, C, Y and W135 to a outer membrane vesicle protein selected from a group consisting of Neisseria meningitides group B serotypes 4 and 15 outer membrane vesicle proteins.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: August 14, 2018
    Assignee: Beijing Sanroad Biological Products Co., Ltd.
    Inventor: Wang Jianhua